LORDS

Manufacture of regenerative treatments

17 December 2012

The House of Lords Science Committee will take evidence from witnesses expert in manufacturing cell therapies and other regenerative treatments. The Committee will quiz the witnesses on how, for example, small scale cell therapy research can be scaled-up to treat large numbers of patients.

The Committee will ask the witnesses what infrastructure needs to be developed to deliver regenerative treatments in the UK, and about the role of the public and private sector in these efforts. It will also discuss the role of the new Cell Therapy Catapult with its Chief Executive.

Witnesses

Tuesday 18 December, Committee Room 4, Palace of Westminster

At 10.40am

  • Dr David Newble, Chief Executive Officer, TAP Biosystems
  • Keith Thompson, Chief Executive Officer, Cell Therapy Catapult Centre
  • Professor David Williams, Director EPSRC Centre for Innovative Manufacturing in Regenerative Medicine, Loughborough University

At 11.40am

  • Dr Zahid Latif, Head of Healthcare, Technology Strategy Board
  • Keith Thompson, Chief Executive Officer, Cell Therapy Catapult Centre

Image: iStockphoto

Share this page